Molecular Partners Reports Corporate Highlights and H1 2022 Financials

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and unaudited financial results for the first half-year of 2022.

“In the first half of this year, we have delivered a major clinical success with ensovibep, leading to its licensure by our partner Novartis and a position of financial strength to execute on the next phase of our strategy at full speed,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. “Programs like ensovibep and our trispecific T-cell engager for AML, MP0533, represent our strategic focus: highly differentiated approaches to major diseases that leverage the strengths of the DARPin class. Using our leading platform, we are focused on advancing and growing our pipeline to meaningfully impact treatment for patients.”


  • Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022
  • Initiation of Phase 1 study for MP0533 expected by year end
  • Continued progression of proprietary DARPin-conjugated radioligand therapeutics;
    innate immune cell engagers; next-generation T-cell engagers; and antiviral DARPins
  • MP0310 Phase 1 enrollment complete; no additional studies currently planned
  • In January 2022, Molecular Partners received a payment of CHF 150 million from Novartis to license ensovibep
  • Novartis is responsible for further development, manufacturing, and commercialization activities. An application for Emergency Use Authorization (EUA) was submitted to the
    U.S. Food and Drug Administration (FDA) by Novartis for ensovibep
  • Cash position of CHF 285.1 million as of June 30, 2022, anticipated to support operations into 2026